Previous 10 | Next 10 |
Author’s note: I am grateful to Dr. Pascaline Clerc, U.S Campaign Manager, The National Education Program. Introduction 2019, designated as the year of NASH in the biotech industry, was the year to demonstrate the clinical achievements in NASH therapeutics. In the beginning of...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
Clinical-stage biopharmaceutical company CymaBay Therapeutics (NASDAQ: CBAY) has closed an underwritten public offering of 9,200,000 shares of its common stock, which includes an additional 1,200,000 shares pursuant to the full exercise of the over-allotment option. According to the update, Cy...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years including 98 weeks of public weekly selections as part of this ongoing live forward-testing. In 2017, the sample size began with 12 stocks, then 8 stocks in...
NEWARK, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver Congress TM of the European Association for the Study of Liver (EASL) in Vienna, Austria from...
The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Interest rates are back in the spotlight with a Federal Reserve interest rate decis...
Nano cap Conatus Pharmaceuticals ( CNAT +22.2% ) is up on more than a 4x surge in volume. Shares have rallied 43% this week. More news on: Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...
NEWARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...